AzTrials
AzTrials

Synthetic Cannabinoid Abuse (Disorder)BonsaiNCT06235346

Ocular Effects of Synthetic Cannabinoids

An observational study of Synthetic Cannabinoid Abuse (Disorder) and Eye Manifestations, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this observational study is to evaluate the ocular effects of Bonzai (synthetic cannabinoids) with spectral-domain optical coherence tomography. Researchers will compare eye findings in patients who have previously used Bonzai with a healthy control group to see if there are ocular effects. Read more about this study

Who is it for?
Any age, men onlyHealthy volunteers can take part
How many people
90 participants
Where
1 siteTurkey (Türkiye)
Study dates
15 Mar 2015to 15 Jan 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Men only
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: The judiciary-supervised probation unit of Alcohol and Substance Research, Treatment and Training Centre (AMATEM) of Department of Psychiatry, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey

Who may be able to join

  • Male patients with past synthetic cannabinoids use and
  • 30 eyes of age-matched 30 male healthy control subjects

Who cannot join

  • present co-use of any substances other than synthetic cannabinoids
  • chronic ocular disease, such as uveitis or glaucoma
  • history of previous ocular surgery
  • systemic disease, such as diabetes mellitus or hypertension
  • systemic or topical drug use that may influence vascular tone, such as topical anti-glaucomatous and systemic anti-hypertensive medications
  • refraction in spherical equivalent (SE) ± 1 dioptre (D) out of range. -

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Bakirkoy Dr. Sadi Konuk Educational and Research Hospital

    Istanbul

Other trials in Turkey (Türkiye)

About this study

Official title: Ocular Effects of Synthetic Cannabinoids: A Case-control Study

The goal of this observational study is to evaluate the ocular effects of Bonzai (synthetic cannabinoids) with spectral-domain optical coherence tomography.

Researchers will compare eye findings in patients who have previously used Bonzai with a healthy control group to see if there are ocular effects.

Read the detailed description

MATERIAL AND METHODS Participants This study was designed as cross-sectional, observational, case-control study. Upon referral from the judiciary-supervised probation unit of Alcohol and Substance Research, Treatment and Training Centre (AMATEM) of the relevant tertiary psychiatry hospital between March 2015 and January 2016, 60 eyes of 60 consecutive male patients with past synthetic cannabinoids (SC) use and 30 eyes of age-matched 30 male healthy control subjects were enrolled in the study in 3 groups: a control group (n=30) included eyes of subjects with no history of use of any substance including tobacco, a seronegative SC group (n=30) included eyes of patients declaring no present use of any substance, as verified by three consecutive negative urine toxicology tests performed two weeks apart, and a seropositive SC group (n=30), including eyes of patients with positive urine toxicology tests proving present use of SC.

SCs and relevant metabolites in urine samples were screened with a direct ELISA kit (K2 Enzyme Immunoassay, Immunalysis Corp., Pomona, CA, USA). This kit was able to detect relevant metabolites, such as JWH-018, JWH-073, and AM-2201, with a cut-off level of 20 ng/mL and over for positive results. Exposures to classical cannabinoids, ecstasy, amphetamines, opioids, and ethylene glycol were also screened.

Regarding SC use, the patients were asked about the duration and the last time of use. In addition, the previous use of other substances was questioned in detail.

Ophthalmic Assessments All eyes underwent ophthalmic examinations, including autorefraction, best-corrected visual acuity (BCVA) testing, biomicroscopy, non-contact IOP measurement, and dilated fundus examination.

An experienced technician performed spectral-domain optical coherence tomography (SD-OCT) imaging of all eyes following pupil dilatation (1% tropicamide) and systolic/diastolic blood pressure measurements (SBP/DBP). All SD-OCT assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation. Only high-quality SD-OCT images with a signal strength index (SSI) greater than 50 were sent for analysis. The parafoveal retinal thickness (parafoveal RT) and central foveal thickness (CFT), CT, peripapillary RNFL thickness, and macular GCC thickness measurements were performed with an RTVue-100 OCT device (Optovue Inc., Fremont, US), which had a 5 µm axial image resolution with a speed of 27,000 A-scans per second.

We preferred the ONH map protocol for examining the RNFL parameters. This protocol creates a RNFL thickness map based on measurements around a circle 3.45 mm in diameter centred on the ONH. The protocol for the GCC scan was based on examining a square grid (7 × 7 mm) on the central macula after centring 1 mm temporal to the macula. The average, superior, and inferior values displayed by the device were studied for the mean GCC and mean RNFL parameters.

Segmental divisions were recorded with the MM5 protocol of the inbuilt software, characterized by a 5 × 5 mm2 grid of 11 horizontal and 11 vertical lines with 668 A-scans and a 3 × 3 mm2 inner grid of 6 horizontal and 6 vertical lines with 400 A-scans for the retinal thickness of a 1 mm diameter CFT. The CT was measured by cross-sectioning through the foveolar centre line, characterized by an 8 mm width, with 1024 A-scans captured on the chorioretinal mode (these settings enable enhanced depth imaging along with contrast and brightness tuning). The line was rotated horizontally and vertically so that manual measurements were taken first at the central foveola and then 750 µm apart in the nasal, temporal, superior, and inferior directions with the ruler function, using a line extending from the posterior edge of the retinal pigment epithelium to the choroidoscleral junction.

The choroidal structure was analysed using the method previously described by Agrawal et al., and all collected images were processed and analysed using the open-source and publicly available ImageJ software (version 1.50a, freely available at http://imagej.nih.gov/ij/; National Institutes of Health [NIH], Bethesda, MD). According to this method, the image was first binarized using the Niblack auto-local thresholding function. This provided a clear visualization of the choroidoscleral interface while also enabling the precise selection of a region of interest, such as the total subfoveal choroidal area (TA). A fovea-centred, 1500 μm wide, nasal-to-temporal subfoveal choroidal area was manually selected using the polygon selection tool. The dark pixels representing the luminal area (LA) were selected using the colour threshold tool, and the residual light pixels were considered the stromal area (SA). The subfoveal CVI was calculated as the ratio of the LA to the TA. Manual measurements (CT and CVI) were carried out by the same experienced investigator blinded to the groups. Each measurement was repeated twice, and the mean of the two measurements was used in the analysis.

Statistical analysis Statistical analysis was conducted with software (SPSS 22.0 Version, IBM Corporation, New York, USA). Descriptive statistics were stated as the mean, standard deviation (SD), or median (Med), the interquartile range (Q1-Q3), and the frequency and ratio (%) values, where appropriate. The distribution of normality was evaluated for each parameter with the Kolmogorov-Smirnov test. Parametric (for normal distribution) or non-parametric tests were applied as appropriate. A parametric analysis of variance (ANOVA) with a post hoc Tukey test or a non-parametric Kruskal-Wallis test with a post hoc Bonferroni-corrected Mann-Whitney U test was used to analyse the independent variables. The chi-square test was used to analyse the qualitative data. Correlations of choroidal thickness measurements with parameters relevant to SC use were studied using the Spearman test.

Keywords
Bonzai, choroid, intraocular pressure, retina, synthetic cannabinoids
Medical subject headings
Eye Manifestations

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06235346
Study groupRoleWhat they receive
Control GroupEyes of subjects with no history of use of any substance
Seronegative Synthetic Cannabinoids GroupEyes of patients declaring no present use of any substance and as verified by three consecutive negative urine toxicology tests performed two weeks apart
Seropositive Synthetic Cannabinoids GroupEyes of patients with positive urine toxicology tests proving present use of synthetic cannabinoids

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraocular pressure

    Intraocular pressure measurement by non-contact air-puff tonometer. Intraocular pressure will be reported in mmHg

    Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.

  2. Central foveal thickness

    All measurements were obtained with the built-in software of the SD-OCT device. Central foveal thickness will be reported in µm.

    Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.

  3. Peripapillary retinal nerve fibre layer thickness

    All measurements were obtained with the built-in software of the SD-OCT device. Peripapillary retinal nerve fibre layer thickness will be reported in µm.

    Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.

  4. Macular ganglion cell complex thickness

    All measurements were obtained with the built-in software of the SD-OCT device. Macular Ganglion cell complex thickness will be reported in µm.

    Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.

  5. Subfoveal and perifoveal choroidal thicknesses

    Choroidal imaging carried out with Spectral domain optical coherence tomography by chorioretinal mode. All choroidal thicknesses were measured with the built-in caliper function. Subfoveal and perifoveal choroidal thicknesses will be reported in µm.

    Measured: All SD-OCT assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.

  6. Choroidal vascularity index

    All choroidal images were exported to ImageJ software and binarized with Niblack autolocal thresholding method. After binarization, dark pixels indicate luminal area, and white pixels indicate stromal area. "Luminal area/total area(stromal+luminal area) * 100" formula will be used for choroidal vascularity index (CVI) calculation. CVI will be reported in %

    Measured: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jan 2024
  2. Study start15 Mar 2015
  3. Primary completion15 Sep 2015
  4. Study completion15 Jan 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06235346
Sponsor's protocol ID
2015/56
Acronym
Bonsai
Status last verified
Jan 2024
First submitted
22 Jan 2024
Last updated
31 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Agrawal R, Salman M, Tan KA, Karampelas M, Sim DA, Keane PA, Pavesio C. Choroidal Vascularity Index (CVI)--A Novel Optical Coherence Tomography Parameter for Monitoring Patients with Panuveitis? PLoS One. 2016 Jan 11;11(1):e0146344. doi: 10.1371/journal.pone.0146344. eCollection 2016.

    PubMed 26751702
  • Kunduraci MS, Kirik F, Onur IU, Onur OS, Karsidag C, Yigit FU, Erkiran M. Ocular effects of synthetic cannabinoids: a case-control study. Eye (Lond). 2025 Jan;39(1):94-101. doi: 10.1038/s41433-024-03381-x. Epub 2024 Oct 8.

    PubMed 39375488

Questions about this trial

What is this clinical trial studying?

An observational study of Synthetic Cannabinoid Abuse (Disorder) and Eye Manifestations, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraocular pressure (time frame: All assessments were conducted between 14:00 and 16:00 to minimize the potential effect of diurnal variation.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06235346, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in